A detailed history of E Fund Management Co., Ltd. transactions in Insmed Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 14,551 shares of INSM stock, worth $964,585. This represents 0.06% of its overall portfolio holdings.

Number of Shares
14,551
Previous 6,815 113.51%
Holding current value
$964,585
Previous $456,000 132.89%
% of portfolio
0.06%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$62.0 - $79.01 $479,632 - $611,221
7,736 Added 113.51%
14,551 $1.06 Million
Q2 2024

Aug 12, 2024

SELL
$22.0 - $69.71 $192,764 - $610,799
-8,762 Reduced 56.25%
6,815 $456,000
Q1 2024

May 13, 2024

SELL
$25.72 - $29.94 $41,177 - $47,933
-1,601 Reduced 9.32%
15,577 $422,000
Q4 2023

Feb 06, 2024

BUY
$23.42 - $31.74 $73,304 - $99,346
3,130 Added 22.28%
17,178 $532,000
Q3 2023

Nov 13, 2023

SELL
$19.86 - $26.93 $117,273 - $159,021
-5,905 Reduced 29.59%
14,048 $355,000
Q2 2023

Aug 11, 2023

SELL
$16.44 - $21.1 $25,087 - $32,198
-1,526 Reduced 7.1%
19,953 $421,000
Q1 2023

May 11, 2023

SELL
$16.26 - $21.73 $23,056 - $30,813
-1,418 Reduced 6.19%
21,479 $366,000
Q4 2022

Feb 14, 2023

BUY
$16.98 - $23.15 $63,029 - $85,932
3,712 Added 19.35%
22,897 $457,000
Q3 2022

Nov 14, 2022

SELL
$20.88 - $28.21 $38,022 - $51,370
-1,821 Reduced 8.67%
19,185 $413,000
Q2 2022

Aug 15, 2022

BUY
$17.07 - $25.71 $151,752 - $228,561
8,890 Added 73.37%
21,006 $414,000
Q1 2022

May 12, 2022

BUY
$20.42 - $28.13 $175,019 - $241,102
8,571 Added 241.78%
12,116 $285,000
Q1 2021

May 12, 2021

BUY
$32.28 - $44.3 $114,432 - $157,043
3,545 New
3,545 $120,000

Others Institutions Holding INSM

About INSMED Inc


  • Ticker INSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 135,476,992
  • Market Cap $8.98B
  • Description
  • Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversibl...
More about INSM
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.